Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute on Key Decisions in HIV Care: Switching to a 2-Drug Single Tablet Regimen

In this case example, learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted.
William R. Short, MD, MPH, AAHIVS
Released: September 28, 2021

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings